论文部分内容阅读
目的:探讨孟鲁司特钠联合抗生素对哮喘患儿T淋巴细胞亚群CD4+和CD8+水平的影响。方法:选取我院收治的哮喘患儿50例,并将其随机分为两组,每组各25例。对照组予常规抗生素治疗,实验组在此基础上加用孟鲁司特钠治疗。观察和比较两组患儿的临床疗效、一年内复发率,以及CD4+、CD8+和CD4+/CD8+比值的变化情况。结果:两组哮鸣音、咳嗽及喘憋持续时间均获得改善,实验组优于对照组,差异有统计学意义(P<0.05)。与同组治疗1天后比较,两组患儿治疗5、10天后的CD4+、CD8+以及CD4+/CD8+比值均明显升高;与同组治疗5天后比较,两组患儿治疗10天后CD4+、CD8+以及CD4+/CD8+比值均明显升高;实验组患儿治疗5天、10天后的CD4+、CD8+以及CD4+/CD8+比值均明显高于对照组,差异均有统计学意义(P<0.05)。两组治疗后CD4+、CD8+以及CD4+/CD8+比值变化呈显著差异(P<0.05)。实验组1年复发率显著低于对照组,差异有统计学意义(P<0.05)。结论:孟鲁司特钠可能通过影响哮喘患儿CD4+、CD8+及CD4+/CD8+水平,改善患儿的临床症状,缩短其住院时间,值得临床推广应用。
Objective: To investigate the effect of montelukast combined with antibiotics on the levels of CD4 + and CD8 + in T lymphocyte subsets in children with asthma. Methods: Fifty children with asthma admitted to our hospital were selected and randomly divided into two groups of 25 cases each. The control group was treated with conventional antibiotics, and the experimental group was treated with montelukast sodium on the basis of this. The clinical efficacy, relapse rate within one year, and the ratio of CD4 +, CD8 + and CD4 + / CD8 + were observed and compared between two groups. Results: The duration of wheeze, cough and wheeze were improved in both groups. The experimental group was better than the control group, the difference was statistically significant (P <0.05). Compared with the same group after treatment for 1 day, the two groups of children treated 5 and 10 days after the treatment of CD4 +, CD8 + and CD4 + / CD8 ratio were significantly increased; compared with the same treatment group after 5 days, 10 days after treatment in both groups, CD4 +, CD8 + The ratio of CD4 +, CD8 + and CD4 + / CD8 + in the experimental group was significantly higher than that in the control group at 5 days and 10 days after treatment. The difference was statistically significant (P <0.05). After treatment, the ratio of CD4 +, CD8 + and CD4 + / CD8 + showed significant difference (P <0.05). The recurrence rate in experimental group was significantly lower than that in control group at one year (P <0.05). Conclusion: Montelukast sodium may affect the level of CD4 +, CD8 + and CD4 + / CD8 + in children with asthma, improve the clinical symptoms and shorten the length of hospital stay in children with asthma, which is worthy of clinical application.